Medicud develops DRYUM, an incisional negative pressure wound therapy system designed to provide constant negative pressure to surgical incisions. DRYUM is single-use, portable and non-electronic, intended to be affordable and to reduce training time for healthcare staff. The company has raised over €1.3M in seed funding and €2.5M in total since inception. Proceeds will be used to initiate the regulatory process and accelerate clinical development, beginning with a first trial in orthopedic surgery (THA and TKA) at Ospedale Pietro e Michele Ferrero in Piedmont, Italy. That trial, led by Prof. Marco Schiraldi, will enroll 59 patients. Medicud plans to expand its team, recruit a commercial director, and pursue a Series A expected in H1 2026 to support commercialization and entry into EU and US markets, targeting cesarean section, total hip and knee arthroplasty, and breast reconstruction after mastectomy.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025